<DOC>
	<DOCNO>NCT01651156</DOCNO>
	<brief_summary>A randomized , double-blind , multicenter , placebo-controlled , parallel study evaluate efficacy safety Tolvaptan treatment patient cardiac edema ( body fluid retention cause congestive heart failure ) base conventional therapy . To evaluate efficacy safety Tolvaptan 15 mg congestive heart failure patient body fluid retention current diuretic treatment , continuous treatment 7 day ' oral Tolvaptan 15mg placebo .</brief_summary>
	<brief_title>Efficacy Safety Study Tolvaptan Treat Patients With Cardiac Edema</brief_title>
	<detailed_description>- A randomized , double-blind , multicenter , placebo-controlled , parallel study - Study population : The congestive heart failure patient body fluid retention receive current diuretic therapy - Number patient : Patients randomly assign Tolvaptan placebo group 1:1 ratio , 120 patient group , 240 patient total - Group assignment method : Tolvaptan 15 mg group : conventional therapy + Tolvaptan 15 mg Placebo group : conventional therapy + placebo - Administration dosage study drug : Once daily , 1 tablet take orally breakfast , successive 7 day - Study period : - Screening period ( 4 day minimum , 7 day maximum ) , include : Screening period : time informed consent form sign Day -4 Observation period : 3 day drug administration - Treatment period : 7 day - Follow visit : Day 8 ( efficacy evaluation day ) Day 7 ( +3 ) last dose - Post treatment survey : Day 14 ( +3 ) last dosing</detailed_description>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Edema , Cardiac</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients treat one oral diuretic therapy standard （include patient treat one oral diuretic therapy standard begin observation period） : 1 . Only 40 mg/day furosemide take orally oral loop diuretic equivalent 40 mg/day furosemide note 1 ) 2 . Combination treatment oral loop diuretic thiazide diuretic ( dosage limitation ) 3 . Combination treatment oral loop diuretic aldosterone antagonist ( dosage limitation ) Because existence excess body fluid retention , congestive heart failure patient least one symptom ( low extremity edema , pulmonary congestion note 2 ) , jugular vein engorgement ) . 2085 year age ( inclusive ) time sign informed consent document . Gender : male female . Inpatients patient would hospitalize one day observation period end efficacy evaluation examination last dosing ( Day 4 end efficacy evaluation examination last dosing ) . Patient sign informed consent form . Patients equip circulatory assistant device . Patients follow disease , complication symptom : 1 . Suspected decreased blood volume 2 . Obstructive hypertrophic cardiomyopathy 3 . Severe aortic stenosis 4 . Hepatic coma Patients history acute myocardial infarction within 30 day prior screen . Patients diagnose active myocarditis amyloid cardiomyopathy . Patients follow disease , complication symptom : 1 . Poorly control diabetes fast glucose 220 mg/dL ( 12.21 mmol/L ) 2 . Anuria 3 . Dysuria cause urethral stricture , calculus tumor Patients follow medical history : 1 . Sustained ventricular tachycardia ventricular fibrillation within 30 day prior screen 2 . History cerebrovascular accident within past 30 day 3 . Past allergy hypersensitive reaction benzodiazepine ( e.g . mozavaptan hydrochloride benazepril hydrochloride ) Obese patient whose body mass index ( BMI = body weight ( kg ) / height ( ) 2 ) 35 . Patients systolic pressure 90 mmHg supine position . Patients follow abnormal laboratory test parameter : 1 . Total bilirubin &gt; 2.5 time upper limit normal value 2 . Serum creatine &gt; 2.5 time upper limit normal value 3 . Serum Na+ &gt; 145 mmol/L ( high upper limit normal value ) 4 . Serum K+ &gt; 5.5 mmol/L Patients unable take medicine orally . Female patient pregnant , breastfeeding , childbearing age , pregnancy plan . Patients participate clinical trial medicine take study drug within 30 day prior sign informed consent form . Patients participate clinical trial Tolvaptan take Tolvaptan previously . Patients receive approved Tolvaptan tablet ( Trade name : Samsca ) previously . Except , patient unsuitable participate trial investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>